We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Purpose
The following guidance aims to assist sponsors and manufacturers in understanding the regulation of borderline disinfectant and related products with antiviral claims (including COVID-19) to determine their regulatory obligations.
The guidance covers a range of borderline products and contains some specific examples to provide clarity on regulation by the TGA.
Due to the COVID-19 pandemic, there has been significant interest from potential sponsors and manufacturers on whether claims made to remove, kill or reduce viruses (such as the virus that causes COVID-19) are permitted under therapeutic goods legislation. Also, whether such claims would render a product a therapeutic good requiring inclusion in the Australian Register of Therapeutic Goods (the ARTG) prior to its importation and/or supply in Australia.
In general, the intended purpose and claims made for a product will determine the type of good and the relevant regulatory requirements the product must comply with. As a general rule, a product that has a therapeutic claim is a therapeutic good.
Advertising requirements
There are laws governing the types of claims that can be made in advertisements for therapeutic goods, including claims that relate to viruses such as COVID-19. For example, claims relating to the advertised good having a virucidal effect are either ‘restricted’ or ‘prohibited’ representations under the Therapeutic Goods Act 1989, which must not be used in advertisements to consumers unless approved or permitted by the TGA.
More information about restricted representations.